natgillin/translations-raw huggingface dataset:
Anti-arrhythmic medicinal products and other substances that may prolong the QT interval
Antiaritmiki in druge snovi, ki lahko podaljšujejo interval QT
What Tasigna is and what it is used for
Kaj je zdravilo Tasigna in za kaj ga uporabljamo
Randomisation was stratified by Sokal risk score at the time of diagnosis.
Randomizacija je bila stratificirana glede na oceno tveganja po Sokalu v času postavitve diagnoze.
What you need to know before you take Tasigna
Kaj morate vedeti, preden boste vzeli zdravilo Tasigna
The doctor will monitor growth at regular visits.
Zdravnik bo pri rednih pregledih spremljal rast otroka.
Therefore the risk that nilotinib causes photosensitisation in patients is considered very low.
Zato je tveganje, da bi nilotinib povzročal fotosenzitivnost, ocenjeno za zelo nizko.
Growth retardation in paediatric population
Zastoj rasti pri pediatrični populaciji
Medical treatment may be necessary.
Morda boste potrebovali zdravniško pomoč.
The primary data analysis time point was when all 846 patients completed 12 months of treatment (or discontinued earlier).
Vnaprej opredeljena časovna točka primarne analize podatkov je bila takrat, ko je vseh 846 bolnikov zaključilo 12 mesecev zdravljenja (oziroma so predhodno prenehali s sodelovanjem).
Among these 88 patients, 86 patients restarted nilotinib treatment and 2 patients permanently discontinued the study.
Med temi 88 bolniki jih je 86 ponovno začelo prejemati nilotinib, 2 bolnika pa sta dokončno prekinila sodelovanje v študiji.
Tasigna hard capsules contain lactose.
Trde kapsule Tasigna vsebujejo laktozo.
Prolongation of the QT interval may expose patients to the risk of fatal outcome.
Podaljšanje intervala QT lahko za bolnika pomeni izpostavljenost smrtni nevarnosti.
If it is used during pregnancy, the patient must be informed of the potential risk to the foetus.
V primeru, da ga bolnica uporablja med nosečnostjo, mora biti seznanjena z možnimi tveganji za plod.
Patients should be advised to seek immediate medical attention if they experience acute signs or symptoms of cardiovascular events.
Bolnike je treba podučiti, da v primeru pojava akutnih znakov ali simptomov srčnožilnih dogodkov takoj poiščejo zdravniško pomoč.
The median time on treatment was approximately 70 months in the nilotinib treatment groups and 64 months in the imatinib group.
Mediana trajanja zdravljenja je bila približno 70 mesecev v skupini z nilotinibom in 64 mesecev v skupini z imatinibom.
- Do not use this medicine after the expiry date which is stated on the carton and blister.
- Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in pretisnem omotu.
Continue taking Tasigna every day for as long as your doctor tells you.
Zdravilo Tasigna jemljite vsak dan in nadaljujte, dokler vam tako svetuje zdravnik.
Since a risk to the newborns/infants cannot be excluded, women should not breast-feed during Tasigna treatment and for 2 weeks after the last dose.
Ker tveganja za dojenega novorojenca/otroka ne moremo izključiti, ženske v času zdravljenja z zdravilom Tasigna in še 2 tedna po prejemu zadnjega odmerka ne smejo dojiti.
If you have any questions about how Tasigna works or why it has been prescribed for you or your child, ask your doctor.
Če imate kakšna vprašanja glede tega, kako zdravilo Tasigna deluje ali zakaj so ga predpisali vam oziroma vašemu otroku, vprašajte svojega zdravnika.
If any of these apply to you or your child, tell your doctor.
Če karkoli od zgoraj navedenega velja za vas ali vašega otroka, povejte svojemu zdravniku.
Safety information from two Tasigna treatment discontinuation studies is also provided.
Navedeni so tudi varnostni podatki iz dveh študij prekinitve zdravljenja z zdravilom Tasigna.
It is unknown whether nilotinib is excreted in human milk.
Ni znano, ali se nilotinib izloča v materino mleko.
If you are taking any of these, your doctor might prescribe other alternative medicines.
Če jemljete katero od teh zdravil, vam bo zdravnik morda predpisal drugo ustrezno zdravilo.
Steady-state conditions were essentially achieved by day 8.
Do stanja dinamičnega ravnovesja je v glavnem prišlo do 8. dne.
No major differences were observed for safety and efficacy in patients ≥65 years of age as compared to adults aged 18 to 65 years.
Pri bolnikih, starih 65 let ali več, niso opažali večjih razlik glede varnosti in učinkovitosti v primerjavi z odraslimi, starimi 18 do 65 let.
Overall, 73% of patients were imatinib-resistant, while 27% were imatinib-intolerant.
Skupno je bilo 73 % bolnikov rezistentnih na imatinib, 27 % pa jih ni prenašalo imatiniba.
Contains lactose - see the package leaflet for further information.
Vsebuje laktozo - za več podatkov glejte Navodilo za uporabo.
The hard capsules should be swallowed whole with water.
Trde kapsule je treba pogoltniti cele z vodo.
The blood-to-plasma ratio of nilotinib is 0.71.
Razmerje vsebnosti kri/plazma je pri nilotinibu 0,71.
Eligibility for discontinuation of treatment
Primernost za prekinitev zdravljenja
You should also tell your doctor if you are already taking Tasigna and you are prescribed a new medicine that you have not taken previously during Tasigna treatment.
Zdravniku morate povedati tudi v primeru, da že jemljete zdravilo Tasigna, pa vam predpišejo novo zdravilo, ki ga prej med zdravljenjem z zdravilom Tasigna še niste jemali.
Since nilotinib and its metabolites are not renally excreted, a decrease in total body clearance is not anticipated in patients with renal impairment.
Ker se nilotinib in njegovi metaboliti ne izločajo preko ledvic, pri bolnikih z okvaro ledvic ni pričakovati znižanja celotnega telesnega očistka.
Genotoxicity studies in bacterial in vitro systems and in mammalian in vitro and in vivo systems with and without metabolic activation did not reveal any evidence for a mutagenic potential of nilotinib.
Študije genotoksičnosti na bakterijskih sistemih in vitro ter na sesalskih sistemih in vitro in in vivo, z metabolično aktivacijo ali brez nje, niso dale nobenega dokaza za mutageni potencial nilotiniba.
However, it is recommended that patients experiencing dizziness, fatigue, visual impairment or other undesirable effects with a potential impact on the ability to drive or use machines safely should refrain from these activities as long as the undesirable effects persist (see section 4.8).
Kljub temu velja priporočilo, da bolniki, pri katerih prihaja do omotičnosti, utrujenosti, motenj vida ali drugih neželenih učinkov, ki bi lahko vplivali na sposobnost varne vožnje ali upravljanja s stroji, ne smejo opravljati teh dejavnosti, dokler neželeni učinki vztrajajo (glejte poglavje 4.8).
CML is a cancer of the blood which makes the body produce too many abnormal white blood cells.
KML je krvni rak, zaradi katerega telo izdeluje preveč nenormalnih levkocitov.
If transient interruption of treatment is not possible, close monitoring of the individual for prolongation of the QT interval is indicated (see sections 4.2, 4.5 and 5.2).
Če začasna prekinitev zdravljenja ni možna, je treba posameznika natančno spremljati glede podaljšanja intervala QT (glejte poglavja 4.2, 4.5 in 5.2).
No effects were seen in ECG measurements in dogs or monkeys treated for up to 39 weeks or in a special telemetry study in dogs.
Vpliva na meritve EKG niso opažali niti pri psih niti pri opicah, ki so jih z nilotinibom zdravili do 39 tednov, niti v posebni telemetrični študiji na psih.
Tasigna should not be used during pregnancy unless the clinical condition of the woman requires treatment with nilotinib.
Zdravila Tasigna ne smete uporabljati med nosečnostjo, razen če je zdravljenje z nilotinibom potrebno zaradi kliničnega stanja ženske.
How to take Tasigna - Swallow the hard capsules whole with water.
Kako jemati zdravilo Tasigna - Trde kapsule pogoltnite cele z vodo.
No deaths were reported on treatment or after treatment discontinuation in both studies.
V nobeni od obeh študij niso poročali o primerih smrti niti v času zdravljenja niti po njegovi prekinitvi.
The hard capsules are red.
Trde kapsule so rdeče.
Subsequent analyses reflect when patients completed 24, 36, 48, 60 and 72 months of treatment (or discontinued earlier).
Nadaljnje analize vključujejo podatke bolnikov po zaključenih 24, 36, 48, 60 in 72 mesecih zdravljenja (oziroma tistih, ki so predhodno prenehali s sodelovanjem).
The following adverse reactions have been derived from post-marketing experience with Tasigna via spontaneous case reports, literature cases, expanded access programmes, and clinical studies other than the global registration trials.
Naslednji neželeni učinki so pridobljeni iz izkušenj v obdobju trženja zdravila Tasigna, in sicer s spontano sporočenimi primeri, iz literaturnih podatkov, iz programov razširjene uporabe in kliničnih študij, drugih kot v okviru globalnih preskušanj za registracijo zdravila.
If clinically significant moderate or severe non-haematological toxicity develops, dosing should be interrupted, and patients should be monitored and treated accordingly.
Če pride do klinično pomembne zmerne ali hude nehematološke toksičnosti, je treba odmerjanje prekiniti in bolnika ustrezno spremljati in zdraviti.
As compared to an oral drink solution (pH of 1.2 to 1.3), relative bioavailability of nilotinib capsule is approximately 50%.
V primerjavi s pitjem peroralne raztopine (z vrednostjo pH od 1,2 do 1,3) je relativna biološka uporabnost nilotiniba iz kapsul približno 50 %.
Food may enhance the absorption of Tasigna and therefore increase the amount of Tasigna in the blood, possibly to a harmful level.
Hrana lahko poveča absorpcijo zdravila Tasigna in tako poveča količino zdravila Tasigna v krvi, lahko tudi toliko, da postane škodljivo.
If you are pregnant or think that you may be, tell your doctor who will discuss with you whether you can take this medicine during your pregnancy.
Če ste noseči ali domnevate, da bi lahko bili, povejte zdravniku, da se bo z vami pogovoril o tem, ali lahko jemljete to zdravilo med nosečnostjo.
The apparent elimination half-life estimated from the multiple-dose pharmacokinetics with daily dosing was approximately 17 hours.
Navidezni razpolovni čas izločanja, ocenjen na podlagi farmakokinetike večkratnih odmerkov pri odmerjanju enkrat dnevno, je bil približno 17 ur.
2 Very common
2 zelo pogosti
These are important in the functioning of the heart.
Ti elektroliti so pomembni za delovanje srca.
Forty patients (58.0%) had relative dose intensity superior to 90%.
Štirideset bolnikov (58,0 %) je prejelo zdravljenje z relativno jakostjo odmerjanja več kot 90 %.
(0.0032% IS < BCR-ABL/ABL ≤0.01% IS).
(0,0032 % po IS < BCR-ABL/ABL ≤0,01 % po IS).
Not all packs may be marketed in your country.
V vaši državi na trgu morda ni vseh navedenih pakiranj.
Do not use more than one teaspoon of apple sauce for each hard capsule and do not use any food other than apple sauce.
Pri tem ne smete uporabiti več kot ene čajne žličke jabolčnega soka za vsako trdo kapsulo in nobenega drugega živila, ki ni jabolčni sok.
If event occurs after dose reduction, consider discontinuing treatment.
Če do dogodka pride po znižanju odmerka, je treba razmisliti o dokončni ukinitvi odmerjanja.
The median highest prior imatinib dose had been 600 mg/day.
Mediana najvišjega predhodnega odmerka imatiniba je bila 600 mg/dan.
Up to 0.32 m
do 0,32 m
Reactivation of hepatitis B in patients who are chronic carriers of this virus has occurred after these patients received BCR-ABL tyrosine kinase inhibitors.
Reaktivacija hepatitisa B pri bolnikih, ki so kronični prenašalci tega virusa, se je pojavila, potem ko so ti bolniki prejeli zaviralce BCR-ABL tirozin-kinaze.
Tasigna was administered on a continuous basis (twice daily 2 hours after a meal and with no food for at least one hour after administration) unless there was evidence of inadequate response or disease progression.
Zdravilo Tasigna so bolniki prejemali neprekinjeno (dvakrat dnevno 2 uri po obroku, po aplikaciji zdravila pa vsaj eno uro niso uživali hrane), razen če so odkrili nezadosten odziv ali napredovanje bolezni.
Therapy should be initiated by a physician experienced in the diagnosis and the treatment of patients with CML.
Zdravljenje mora začeti zdravnik, izkušen v diagnostiki in zdravljenju bolnikov s KML.
In paediatric patients, treatment must be interrupted until the event returns to Grade 1.
Pri pediatričnih bolnikih je treba zdravljenje prekiniti, dokler se vrednosti ne znižajo do stopnje 1.
Do not stop taking this medicine unless your doctor tells you to do so.
Ne prenehajte jemati tega zdravila, če vam tega ni naročil zdravnik.
Since these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to nilotinib exposure.
Ker so o teh neželenih učinkih poročali spontano pri bolnikih iz populacij nedoločljive velikosti, ni vedno mogoče zanesljivo določiti pogostnosti teh neželenih učinkov oziroma ugotoviti njihove vzročne povezave z izpostavljenostjo nilotinibu.
Carcinogenicity studies
Študije karcinogenosti
Isolated reports of intentional overdose with nilotinib were reported, where an unspecified number of Tasigna hard capsules were ingested in combination with alcohol and other medicinal products.
Poročali so o posameznih primerih namernega zaužitja prevelikega odmerka nilotiniba, v katerih so posamezniki zaužili neopredeljeno število trdih kapsul zdravila Tasigna skupaj z alkoholom in drugimi zdravili.
Other medicines and Tasigna Tasigna may interfere with some other medicines.
Druga zdravila in zdravilo Tasigna Zdravilo Tasigna lahko vpliva na nekatera druga zdravila in obratno.
Patients were within six months of diagnosis and were previously untreated, with the exception of hydroxyurea and/or anagrelide.
Bolnikom so postavili diagnozo v zadnjih šestih mesecih pred vključitvijo v študijo in predhodno še niso bili zdravljeni, razen s hidroksiureo in/ali z anagrelidom.
Rifampicin, a potent CYP3A4 inducer, decreases nilotinib Cmax by 64% and reduces nilotinib AUC by 80%.
Rifampicin, ki je močan induktor CYP3A4, zniža Cmax nilotiniba za 64 % in zmanša njegovo AUC za 80 %.
The absolute bioavailability of nilotinib has not been determined.
Absolutne biološke uporabnosti nilotiniba niso določali.
In vitro, nilotinib is a relatively strong inhibitor of CYP3A4, CYP2C8, CYP2C9, CYP2D6 and UGT1A1, with Ki value being lowest for CYP2C9 (Ki=0.13 microM).
In vitro je nilotinib sorazmerno močan zaviralec CYP3A4, CYP2C8, CYP2C9, CYP2D6 in UGT1A1, pri čemer je vrednost Ki najnižja za CYP2C9 (Ki=0,13 mikroM).
The heart rate will also be checked using a machine that measures electrical activity of the heart (a test called an “ECG”).
Z napravo za merjenje električne aktivnosti srca vam bodo posneli srčni utrip (preiskava se imenuje “EKG”).
If you are the parent of a child who is being treated with Tasigna, tell the doctor if any of the above conditions apply to your child.
Če imate otroka, ki ga zdravijo z zdravilom Tasigna, zdravniku povejte, če karkoli od zgoraj navedenega morda velja za vašega otroka.
Older people (age 65 years and over) Tasigna can be used by people aged 65 years and over at the same dose as for other adults.
Starejši ljudje (stari 65 let in več) Ljudje, stari 65 let in več, lahko uporabljajo zdravilo Tasigna v enakih odmerkih kot drugi odrasli.
Show them the pack of hard capsules and this package leaflet.
Pokažite jim škatlo s trdimi kapsulami in to Navodilo za uporabo.
Tasigna may be given in combination with haematopoietic growth factors such as erythropoietin or granulocyte colony-stimulating factor (G-CSF) if clinically indicated.
Zdravilo Tasigna se lahko daje v kombinaciji s hematopoetskimi rastnimi dejavniki, kot sta eritropoetin ali granulocitne kolonije stimulirajoči faktor (G-CSF), če je to klinično indicirano.
- Do not use this medicine if you notice that the pack is damaged or shows signs of tampering.
- Ne uporabljajte tega zdravila, če opazite, da je ovojnina poškodovana ali da je bila že odprta.
Complete cytogenetic response (CCyR) was defined as 0% Ph+ metaphases in the bone marrow based on a minimum of 20 metaphases evaluated.
Popolni citogenetični odziv (CCyR) je bil opredeljen kot 0 % Ph+ metafaz v kostnem mozgu na osnovi pregledanih najmanj 20 metafaz.
After imatinib failure, 24 different BCR-ABL mutations were noted in 42% of chronic phase and 54% of accelerated phase CML patients who were evaluated for mutations.
Po neuspešnem zdravljenju z imatinibom so zabeležili 24 različnih BCR-ABL mutacij pri 42 % bolnikov v kronični fazi in pri 54 % bolnikov v pospešeni fazi KML, ki so jih pregledovali glede mutacij.
Besides standard study parameters, evaluations of developmental landmarks, CNS effects, mating and fertility were performed.
Poleg standardnih študijskih parametrov so ocenjevali še razvojne mejnike, vpliv na osrednje živčevje, parjenje in plodnost.
Patients who lose MMR must re-initiate treatment within 4 weeks of when loss of remission is known to have occurred.
Bolniki, pri katerih pride do izgube odziva MMR, morajo ponovno začeti z zdravljenjem v 4 tednih od takrat, ko je bilo ugotovljeno poslabšanje po remisiji.
The juvenile animals did not exert increased sensitivity to nilotinib relative to adults.
V primerjavi z odraslimi živalmi pri mladičih ni bilo opaziti povečane občutljivost za nilotinib.
Median duration of therapy in days (25th-75th percentiles)
mediana trajanja zdravljenja v dnevih (25.-75. percentil)
Complete blood counts should be performed every two weeks for the first 2 months and then monthly thereafter, or as clinically indicated.
V prvih 2 mesecih je treba pregledati kompletno krvno sliko vsaka dva tedna, kasneje pa enkrat mesečno oziroma glede na klinične potrebe.
There is no experience with the use of this medicine in children below 2 years of age.
Z uporabo tega zdravila pri otrocih, ki so stari manj kot 2 leti, ni nobenih izkušenj.
The long-term effects of treating children with Tasigna for long periods of time are not known.
Dolgoročni učinki dolgotrajnega zdravljenja otrok z zdravilom Tasigna niso znani.
It may be given with hydroxyurea or anagrelide if clinically indicated.
Lahko se daje s hidroksiureo ali z anagrelidom, če je to klinično indicirano.
Table 5 Grade 3-4 laboratory abnormalities*
Preglednica 5 Nepravilnosti laboratorijskih izvidov pri stopnji 3-4*
Table 6 Kinase profile of nilotinib (phosphorylation IC50 nM)
Preglednica 6 Pregled učinka nilotiniba na kinaze (IC50 nM za fosforilacijo)
Based on a reduction in body weight in both genders and a delayed preputial separation in males (which may be associated with the reduction in weight), the No-Observed-Effect-Level in juvenile rats was considered to be 6 mg/kg/day.
Na podlagi zmanjšanja telesne mase pri obeh spolih in kasnejšega ločevanja prepucija pri samcih (kar je lahko povezano z zmanjšanjem telesne mase) menijo, da je višina odmerka brez opaznega škodljivega učinka 6 mg/kg/dan.
Haematological Response (%) Overall (95%CI) Complete NEL
hematološki odziv (%) vsi skupaj (95-odstotni IZ) popolni
It is therefore crucial to perform frequent monitoring of BCR-ABL transcript levels and complete blood count with differential in order to detect possible loss of remission (see section 4.2).
Iz tega razloga je ključnega pomena pogosto določanje ravni prepisov BCR-ABL in kompletne krvne slike skupaj z diferencialno krvno sliko z namenom ugotavljanja morebitnega poslabšanja po remisiji (glejte poglavje 4.2).
Of these patients 30/36 (83%) were treatment resistant not intolerant.
Izmed 36 bolnikov jih je bilo 30 (83 %) rezistentnih na zdravljenje oziroma ga niso prenašali.
Accelerated phase (n=137)*
pospešena faza (n=137)*
Final CSR: April 2021
april 2021
In case lipase elevations are accompanied by abdominal symptoms, nilotinib therapy should be interrupted and appropriate diagnostic measures considered to exclude pancreatitis.
V primeru, da so ob zvišanju koncentracije lipaze prisotni tudi abdominalni simptomi, je treba jemanje nilotiniba prekiniti in razmisliti o ustreznih diagnostičnih ukrepih za izključitev možnosti pankreatitisa.
Median duration of treatment was 561 days for CP patients and 264 days for AP patients (see Table 10).
Zdravljenje je mediano trajalo 561 dni pri bolnikih v kronični fazi in 264 dneva pri bolnikih v pospešeni fazi (glejte preglednico 10).
Nilotinib did not have effects on CNS or respiratory functions.
Nilotinib ni vplival na centralno živčevje oziroma na dihalne funkcije.
Patients with BCR-ABL levels ≤10% at 3 months of treatment show a greater overall survival at 72 months compared to those who did not achieve this molecular response level (94.5% vs. 77.1% respectively [p=0.0005]).
Pri bolnikih z ravnijo BCR-ABL ≤10 % po 3 mesecih zdravljenja je bila stopnja celokupnega preživetja po 72 mesecih večja v primerjavi s tistimi, ki niso dosegli te ravni molekularnega odziva (94,5 % v primerjavi z 77,1 %, [p=0,0005]).
- Breast-feeding is not recommended during treatment with Tasigna and for two weeks after the last dose.
- Dojenje ni priporočeno v času jemanja zdravila Tasigna in še dva tedna po zadnjem odmerku.
Pharmacotherapeutic group: Antineoplastic agents, protein kinase inhibitors, ATC code: L01XE08
Farmakoterapevtska skupina: zdravila z delovanjem na novotvorbe, zaviralci protein kinaze, oznaka ATC: L01XE08
Safety pharmacology studies
Farmakološke študije varnosti
Women of childbearing potential have to use highly effective contraception during treatment with nilotinib and for up to two weeks after ending treatment.
Ženske v rodni dobi morajo med zdravljenjem z nilotinibom in še dva tedna po zaključku zdravljenja uporabljati zelo učinkovito kontracepcijo.
For a dose of 400 mg once daily (see dose adjustments below), 200 mg hard capsules are available.
Za odmerjanje 400 mg enkrat dnevno (glejte prilagajanje odmerkov spodaj) so na voljo 200-miligramske trde kapsule.
Tasigna demonstrated efficacy in patients harboring a variety of BCR-ABL mutations associated with imatinib resistance, except T315I.
Zdravilo Tasigna je bilo učinkovito pri bolnikih z različnimi BCR-Abl mutacijami, povezanimi z rezistenco na imatinib, z izjemo T315I.
If your doctor recommends that you discontinue treatment with Tasigna Your doctor will regularly evaluate your treatment with a specific diagnostic test and decide whether you should continue to take this medicine.
Če vam zdravnik priporoči, da prekinete zdravljenje z zdravilom Tasigna Zdravnik bo redno ocenjeval vaše zdravljenje s pomočjo specifičnih diagnostičnih preiskav in presojal, ali je pri vas potrebno nadaljnje zdravljenje s tem zdravilom ali ne.
There is a limited amount of data on pregnancies in patients while attempting treatment-free remission (TFR).
O nosečnosti pri bolnicah v času poskušanja vzdrževanja remisije brez zdravljenja (TFR - treatment-free remission) je na voljo le malo podatkov.
Tasigna is available in a wallet containing 28 hard capsules and in a carton containing 28 or 40 hard capsules.
Zdravilo Tasigna je na voljo v zloženkah, ki vsebujejo 28 trdih kapsul in v škatlah, ki vsebujejo 28 ali 40 trdih kapsul.
The long-term effects of prolonged treatment with nilotinib in paediatric patients are unknown.
Dolgoročni učinki dolgotrajnega zdravljenja z nilotinibom pri pediatrični populaciji niso znani.
Repeated-dose toxicity studies in dogs of up to 4 weeks' duration and in cynomolgus monkeys of up to 9 months' duration revealed the liver as the primary target organ of toxicity of nilotinib.
Študije toksičnosti ponovljenih odmerkov s psi, ki so trajale do 4 tedne, in z opicami vrste javanski makak, ki so trajale do 9 mesecev, so razkrile, da so glavni tarčni organ toksičnosti nilotiniba jetra.
If you have questions about how long to take Tasigna, talk to your doctor.
Če imate vprašanja o tem, kako dolgo je treba jemati zdravilo Tasigna, se pogovorite z zdravnikom.
Imatinib intolerance included patients who discontinued imatinib because of toxicity and were not in major cytogenetic response at time of study entry.
Neprenašanje imatiniba je vključevalo bolnike, ki so prenehali jemati imatinib zaradi toksičnosti, ob vstopu v študijo pa niso kazali pomembnega citogenetičnega odziva.